BRCA promoter methylation in triple-negative breast cancer is preserved in xenograft models and represents a potential therapeutic marker for PARP inhibitors
Authors:
Open Access
- 11 October 2024
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 209 (2) , 389-396
Abstract
Purpose: Most triple-negative breast cancers (TNBC) are sporadic in nature and often associated with dysfunction of the BRCA1 or BRCA2 genes. Since somatic BRCA mutations are rare in breast cancer (BC), this dysfunction frequently is the result of BRCA promoter methylation. Despite the phenotypic similarities of these tumors to those with germline or somatic BRCA mutation, the evidence of response to PARP inhibitors is unclear. Methods: We analyzed the prevalence of BRCA promoter methylation in 29 BC metastases through the well-established Illumina Infinium EPIC Human Methylation Bead Chip. In cases with BRCA methylation, the xenograft of the same tumor was tested. Additionally, we compared BC xenografts with an identified BRCA methylation to their matched primary tumors and subsequently investigated the efficacy of PARP inhibitors on tumor organoids from a BRCA2 promoter-methylated BC. Results: BRCA2 promotor hypermethylation was identified in one pleural metastasis of a young patient as well as in the xenograft tissue. We also identified five more xenograft models with BRCA2 promotor hypermethylation. Analysis of one matched primary tumor confirmed the same BRCA2 methylation. PARP inhibitor treatment of tumor organoids derived from the BRCA2 methylated xenograft tumor tissue of the young patient showed a significant decline in cell viability, similar to organoids with somatic BRCA1 mutation, while having no effect on organoids with BRCA1 wildtype. Conclusion: BRCA promotor hypermethylation seems to be a rare event in metastatic BC but is preserved in subsequent xenograft models and might represent an attractive therapeutic marker for PARP inhibitors.Keywords
Funding Information
- Dr Hans Altschüler Stiftung
- Illumina
- European Research Council (ERC advanced grant 694033 STEM-BCPC, ERC advanced grant 694033 STEM-BCPC, ERC advanced grant 694033 STEM-BCPC, ERC advanced grant 694033 STEM-BCPC, ERC advanced grant 694033 STEM-BCPC, ERC advanced grant 694033 STEM-BCPC, ERC advanced grant 694033 STEM-BCPC)
- the Swiss National Science Foundation
- the Krebsliga Beider Basel
- the Swiss Cancer League
- The Swiss Personalized Health Network
- Department of Surgery, University Hospital Basel
- University of Basel
This publication has 39 references indexed in Scilit:
- Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical reviewCancer Treatment Reviews, 2023
- Homologous recombination deficiency in triple negative breast cancerThe Breast, 2019
- Epigenetic modulation of BRCA‐1 and MGMT genes, and histones H4 and H3 are associated with breast tumorsJournal of Cellular Biochemistry, 2019
- A Living Biobank of Breast Cancer Organoids Captures Disease HeterogeneityCell, 2018
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation CarriersJAMA, 2017
- Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast CancerClinical Breast Cancer, 2015
- Pyrosequencing analysis of BRCA1 methylation level in breast cancer cellsTumor Biology, 2013
- BRCA1 promoter methylation is associated with increased mortality among women with breast cancerBreast Cancer Research and Treatment, 2008
- Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotypeCancer, 2007
- Prognostic markers in triple‐negative breast cancerCancer, 2006